Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

NCT02675439 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

47

Enrollment

INDUSTRY

Sponsor class

Stopped No substantial anti-tumor activity was observed.

Conditions

Advanced/Metastatic Solid Tumors or Lymphomas

Interventions

DRUG: ADU-S100
BIOLOGICAL: ipilimumab

Sponsor

Chinook Therapeutics, Inc. (formerly Aduro)

Collaborators

[object Object]